-
Beyond the injection: How Camurus is developing longer-acting medicines
Camurus specialises in long-acting medicines designed to extend the time between injections. As the drug delivery landscape changes, the company believes its technology gives it a distinct position and a window of opportunity in the market. This is the third part of a Life Science Focus series exploring the shift towards subcutaneous drug administration.
-
Regulatory milestone strengthens Xinnate’s EB program
Xinnate has received a notification from the U.S. Food and Drug Administration (FDA) that may bring significant advantages in the development of the company’s treatment for the skin disease Epidermolysis Bullosa (EB).
-
Sweden takes new steps to tackle oestrogen shortages
Sweden has struggled with shortages of oestrogen medicines for years, forcing women going through the menopause to switch products or search from pharmacy to pharmacy. Now, new measures aim to make it easier for healthcare professionals to find alternatives – including medicines not marketed in Sweden.
-
Smärtprojekt får särläkemedelstatus i EU – ”Stärker våra konkurrensfördelar”
Alzecure Pharma har beviljats särläkemedelsstatus i EU för sitt smärtpreparat ACD440 som behandling vid den sällsynta sjukdomen erytromelalgi.
Get access to all content on Life Science Focus
No commitment or card information required
Already a subscriber? Log In
Applies to personal subscription only.
Contact us for a enterprise solution.
Advertisement
Advertisement
Advertisement
Advertisement
BREAKING